Clinical Trial Update: Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports completed Phase 1/Phase 2 studies evaluating the combination of ofatumumab and dinaciclib in patients with relapsed or refrac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Dinaciclib (dinaciclib)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-03-15